Literature DB >> 1855974

Role of host cellular response in differential susceptibility of nonimmunized BALB/c mice to Plasmodium berghei and Plasmodium yoelii sporozoites.

Z M Khan1, J P Vanderberg.   

Abstract

We found BALB/c mice to be on the order of 2,000 times more susceptible to Plasmodium yoelii than Plasmodium berghei sporozoites, as measured by the ability of these sporozoites to differentiate into microscopically detectable hepatic schizonts in the livers of immunologically naive mice. One of the factors that determine the relative insusceptibility of mice to P. berghei sporozoites is the innate cellular inflammatory response that the mice mount after injection with sporozoites. The cellular inflammatory response against P. berghei is initiated soon after sporozoite injection; by 24 h, substantial histopathological changes have developed within the liver. There is considerably less of a cellular inflammatory response against P. yoelii; significant histopathological changes within the liver are not observed until well after hepatic schizonts have begun to rupture at around 44 h postinjection of sporozoites. These differences in the cellular inflammatory response against two different, closely related species of sporozoites are of considerable interest. The data strongly suggest that the BALB/c-P. berghei sporozoite system is a relatively poor biological model for sporozoite immunization studies.

Entities:  

Mesh:

Year:  1991        PMID: 1855974      PMCID: PMC258051          DOI: 10.1128/iai.59.8.2529-2534.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  7 in total

Review 1.  Rationale for the development of an engineered sporozoite malaria vaccine.

Authors:  V Nussenzweig; R S Nussenzweig
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Plasmodium berghei: quantitation of sporozoites injected by mosquitoes feeding on a rodent host.

Authors:  J P Vanderberg
Journal:  Exp Parasitol       Date:  1977-06       Impact factor: 2.011

3.  Rodent plasmodia of the République Centrafricaine: the sporogony and tissue stages of Plasmodium chabaudi and P. berghei yoelii.

Authors:  I Landau; R Killick-Kendrick
Journal:  Trans R Soc Trop Med Hyg       Date:  1966       Impact factor: 2.184

4.  Further studies on the Plasmodium berghei-Anopheles stephensi--rodent system of mammalian malaria.

Authors:  J P Vanderberg; R S Nussenzweig; H Most
Journal:  J Parasitol       Date:  1968-10       Impact factor: 1.276

5.  Susceptibility of genetically standardized (JAX) mouse strains to sporozoite- and blood-induced Plasmodium berghei infections.

Authors:  H Most; R S Nussenzweig; J Vanderberg; R Herman; M Yoeli
Journal:  Mil Med       Date:  1966-09       Impact factor: 1.437

6.  Plasmodium sporozoite interactions with macrophages in vitro: a videomicroscopic analysis.

Authors:  J P Vanderberg; S Chew; M J Stewart
Journal:  J Protozool       Date:  1990 Nov-Dec

Review 7.  Host-parasite interactions and immunity to irradiated sporozoites.

Authors:  W R Weiss
Journal:  Immunol Lett       Date:  1990-08       Impact factor: 3.685

  7 in total
  32 in total

1.  Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials.

Authors:  J A Vaughan; L F Scheller; R A Wirtz; A F Azad
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.

Authors:  O Bruña-Romero; G González-Aseguinolaza; J C Hafalla; M Tsuji; R S Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  Improved quantification of Plasmodium exoerythrocytic forms in rodents.

Authors:  S Chatterjee; E Ngonseu; P Druilhe; E Van Marck
Journal:  Parasitol Res       Date:  2004-02-12       Impact factor: 2.289

4.  Alterations in Phosphorylation of Hepatocyte Ribosomal Protein S6 Control Plasmodium Liver Stage Infection.

Authors:  Elizabeth K K Glennon; Laura S Austin; Nadia Arang; Heather S Kain; Fred D Mast; Kamalakannan Vijayan; John D Aitchison; Stefan H I Kappe; Alexis Kaushansky
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

5.  Neither mosquito saliva nor immunity to saliva has a detectable effect on the infectivity of Plasmodium sporozoites injected into mice.

Authors:  Chahnaz Kebaier; Tatiana Voza; Jerome Vanderberg
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

6.  TREM2 governs Kupffer cell activation and explains belr1 genetic resistance to malaria liver stage infection.

Authors:  Lígia Antunes Gonçalves; Lurdes Rodrigues-Duarte; Joana Rodo; Luciana Vieira de Moraes; Isabel Marques; Carlos Penha-Gonçalves
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

7.  Plasmodium yoelii-infected A. stephensi inefficiently transmit malaria compared to intravenous route.

Authors:  Solomon Conteh; Rana Chattopadhyay; Charles Anderson; Stephen L Hoffman
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

8.  Alpha-tocopherol transfer protein disruption confers resistance to malarial infection in mice.

Authors:  Maria S Herbas; Yoshiko Y Ueta; Chie Ichikawa; Mayumi Chiba; Kana Ishibashi; Mototada Shichiri; Shinya Fukumoto; Naoaki Yokoyama; Motohiro Takeya; Xuenan Xuan; Hiroyuki Arai; Hiroshi Suzuki
Journal:  Malar J       Date:  2010-04-19       Impact factor: 2.979

9.  Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites.

Authors:  Ian A Cockburn; Yun-Chi Chen; Michael G Overstreet; Jason R Lees; Nico van Rooijen; Donna L Farber; Fidel Zavala
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

10.  Class II-restricted protective immunity induced by malaria sporozoites.

Authors:  Giane A Oliveira; Kota Arun Kumar; J Mauricio Calvo-Calle; Caroline Othoro; David Altszuler; Victor Nussenzweig; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.